The Chemours Company (NYSE:CC) shares traded higher Thursday after the company, DuPont, and Corteva reached a $455 million settlement resolving PFAS-related litigation in North Carolina.

The gain came despite broader weakness, with the S&P 500 down 0.43% and the Materials sector falling 1.24%.

Chemours’ Share Covered By Existing Accruals

Chemours, DuPont de Nemours, Inc. (NYSE:DD), and Corteva, Inc. (NYSE:CTVA) reached a $455 million settlement with North Carolina and 11 local entities over PFAS-related claims tied to Fayetteville Works and other alleged contamination, including AFFF.

Payments will be made over 15 years. Chemours will fund 50% under the companies’ 2021 MOU, with its share valued at approximately $180 million on a net present value basis and covered by existing accruals. About $50 million is expected over the next 12 months.

Of the total settlement, $18 million relates to alleged PFAS contamination unrelated to Fayetteville Works.

See More: Top Value Stocks

Settlement Eliminates Future Escrow Contributions

For qualified-spend purposes under the MOU, the settlement will count as approximately $210 million.

The agreement also satisfies all future escrow contributions, including Chemours’ $50 million payment due in September 2026.

Agreement Addresses Remaining Obligations

The settlement recognizes progress under Chemours’ 2019 Consent Order with North Carolina and establishes procedures for remaining off-site obligations, including drinking water programs.

Chemours said the agreement provides greater clarity around legacy liabilities and supports continued operations at Fayetteville Works.

CC Technical Outlook: Trend Repair Continues

CC remains in a longer-term recovery phase, trading 1.5% below its 20-day SMA of $15.56 and 7.5% below its 50-day SMA of $16.57.

Wider gaps from the 100-day and 200-day averages reinforce the broader weakness.

The August death cross, when the 50-day SMA fell below the 200-day SMA, also keeps the longer-term trend under pressure until shares reclaim key moving averages.

Momentum, however, is improving. The MACD remains above its signal line with a positive histogram, suggesting selling pressure is easing, and buyers are gaining traction.

  • Key Resistance: $16.50 — near the 50-day SMA and a potential hurdle for rebounds.
  • Key Support: $15.00 — a near-term level buyers will look to defend.

How Chemours (CC) Ranks On Momentum And Value

The Benzinga Edge scorecard highlights a mixed setup for Chemours compared with the broader market:

  • Momentum: Weak (Score: 9.47) — Shares continue to lag on trend strength, consistent with the stock trading below key moving averages.
  • Value: Neutral (Score: 35.49) — The valuation profile sits closer to the middle of the market rather than signaling a clear value opportunity.

The Verdict: Chemours shows weak momentum and a neutral valuation profile, leaving the overall Benzinga Edge setup mixed.

Read Also: DuPont Says It Is Exploring M&A Opportunities in Water and Healthcare

CC Price Action: Chemours shares were up 1.53% at $15.27 at the time of publication on Thursday, according to Benzinga Pro data.

Photo by Katherine Welles via Shutterstock